Develops oncology drugs for orphan and paediatric cancers
| Date | Round | Amount |
|---|---|---|
| Oct 2023 | Series B Irish-US pharma Shorla Oncology raised a $35m Series B led by Kurma Partners (Growth Opportunities Fund) with Seroba Life Sciences and Enterprise Ireland to advance its oncology portfolio. | $35M |
Tap an investor to see what else they have backed.
Data is community-curated and may be incomplete.